NASDAQ NMS - GLOBAL MARKET · ORIC
-0.94% · -$0.1200 · Vol 836.0K
Market closed · last close 4:00 PM ET · price as of 16:31:41 ET
Oric Pharmaceuticals Inc

Oric Pharmaceuticals Inc

Biotechnology
$12.67
Card
Relationship Map

Follow $ORIC

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ORIC by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
ORIC
Oric Pharmaceuticals Inc
Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Highest qualified

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

81/ 100
Veridion Score
Highest qualified · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ORIC moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ORIC catalysts
About Oric Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
111
Country
US

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$12.98
Day high
$13.01
Day low
$12.50
Previous close
$12.79
52W high
$14.65
-13.52% from high
52W low
$7.47
72% of range
Market cap
$1.3B
EPS
$-1.5200
Beta
1.91
Shares out
103.7M
Volume
836K
0.69× rel vol
Avg volume
1.2M
VWAP
$12.69
Price history computed in-house
1W
+2.51%
1M
-10.77%
3M
+34.36%
1Y
+17.10%
YTD
+54.89%
SMA 50 $12.53 · above
SMA 200 $10.71 · above
52W position 72%

ORIC overview

Veridion Score
81
Registered · 2026-09-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ORIC.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ORIC Form 4 filings
Public disclosures

Congress activity in ORIC

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ORIC in the cached public ledger.

Federal contracts

ORIC contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ORIC in this window.
Lobbying spend

ORIC lobbying filings, year to date.

Registered lobbying filings matched to Oric Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ORIC in this window.
Loading news for ORIC
Analyst ratings
Sovereign unlock shows live analyst consensus for ORIC.
Options
Sovereign unlock shows live options positioning for ORIC.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.